



TEGSEDI is a registered trademark of Akcea Therapeutics, Inc. © 2020, Akcea Therapeutics, Inc. All rights reserved.  
US-TEG-2000058 05/20

## TEGSEDI® PATIENT WALLET CARD

Carry this card with you at all times. **SHOW THIS CARD** if you go to the emergency room or see any healthcare provider.

Tell any healthcare provider that sees you that you are being treated with **TEGSEDI**.

**Prescriber's name (first & last):**

---

**Prescriber's phone #:**

---



## Patient information

TEGSEDI may cause side effects that are severe or life threatening.

Call your doctor or go to the emergency room **RIGHT AWAY** if you have any of these symptoms:

- Unusual bruising or a rash of tiny reddish-purple spots, often on the lower legs
- Bleeding from skin cuts that does not stop or oozes
- Bleeding from your gums or nose
- Blood in urine or stools
- Bleeding into the whites of your eyes
- Sudden severe headaches or neck stiffness
- Vomiting blood or coughing up blood
- Abnormal or heavy menstrual periods
- Puffiness or swelling in your face, feet, or hands
- New onset or worsening shortness of breath and coughing
- Blood in your urine or brown urine
- Foamy urine (proteinuria)
- Passing less urine than usual

## Important information for healthcare providers

This patient is receiving TEGSEDI for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

TEGSEDI has a risk of serious bleeding with severe thrombocytopenia and a risk of glomerulonephritis. Patients treated with TEGSEDI are being regularly monitored for these risks via the following lab results: platelets, estimated glomerular filtration rate (eGFR), urinalysis, and urine protein to creatinine ratio (UPCR).